DaVita shares fell about 7% in after-hours trading Tuesday even after the company reported second-quarter financial results that beat expectations on both the top and bottom lines and maintained its 2026 guidance. Adjusted diluted earnings per share for the full year is projected at $14.10 to $15.20, compared with a consensus estimate of $14.88. Non-GAAP earnings per share for the second quarter came in at $4.02, up from $2.95 in the same period a year ago. Revenue per treatment declined $1.72 from the first quarter to $415.87, while patient care costs per treatment fell $2.71 to $277.40. The company repurchased 2.2 million shares for $348 million during the quarter and ended the period with cash, cash equivalents, restricted cash, and short-term investments of approximately $771.8 million, down from roughly $782.1 million at the end of December.
DaVita HealthCare Partners IncShares fell 7% despite beating Q2 estimates and reaffirming guidance, likely due to revenue per treatment decline and lower cash position.
